Basic facts about the GAVI Alliance Speaker Event/meeting Location, Date.
-
Upload
arron-west -
Category
Documents
-
view
222 -
download
0
Transcript of Basic facts about the GAVI Alliance Speaker Event/meeting Location, Date.
Basic facts about the GAVI Alliance
Speaker
Event/meeting
Location, Date
Basic facts about GAVIDATE
Overview
1. About the GAVI Alliance
2. Accelerated vaccine uptake
3. Rising demand
4. Innovative financing
5. Shaping the market
6. Programmes of support for countries
7. Moving forward
Basic facts about GAVIDATE
The GAVI Alliance: an innovative partnership
Basic facts about GAVIDATE
The GAVI Alliance Board committee structure
Basic facts about GAVIDATE
GAVI’s mission
To save children’s lives and protect people’s health by increasing access to immunisation in poor countries
WHO/Jim Holmes
Basic facts about GAVIDATE
Four strategic goals
Accelerate the uptake and use of underused and new vaccines
Contribute to strengthening the capacity of integrated health systems to deliver immunisation
Increase the predictability of global financing and improve the sustainability of national financing for immunisation
Shape vaccine markets
Basic facts about GAVIDATE
GAVI making a difference
Catalysing accelerated uptake of vaccines Prevented more than 5 million future deaths Projected 288 million additional children immunised
Supporting increasing country demand Rising demand for new and underused vaccines US$ 5.9 billion committed to countries
Introducing innovative financing mechanisms IFFIm raised more than US$ 3 billion on capital markets AMC pilot accelerates access to pneumococcal vaccines
Shaping markets for vaccines More manufacturers producing more appropriate vaccines Increased capacity secures supply, decreases prices
Basic facts about GAVIDATE
Overview
1. About the GAVI Alliance
2. Accelerated vaccine uptake
3. Rising demand
4. Innovative financing
5. Shaping the market
6. Programmes of support for countries
7. Moving forward
Basic facts about GAVIDATE
Over five million future deaths prevented
Source: These estimates and projections are produced by the WHO Department of Immunization, Vaccines and Biologicals, based on the most up to date data and models available as of November 2010
Results from routine immunisation and one-off tactical investments, by vaccine
Basic facts about GAVIDATE
A strong platform
82% of children now reached through routine immunisation programmes
Immunisation closer to universal coverage than most other health interventions
Enables rapid introduction of life-saving vaccines
Important opportunity to deliver other child and maternal health services
Basic facts about GAVIDATE
A strong platform
Source: WHO; UN DESA, Population Division
Basic facts about GAVIDATE
Immunisation coverage continues to rise
12
Source: WHO-UNICEF coverage estimates for 1980-2009, as of July 2010; WHO ICE- T coverage projections for 2010-2011, as of September 2010; World Population Prospects, the 2008 revision. New York, United Nations, 2009; (surviving infants).
DTP3, hepatitis B and Hib vaccine coverage in GAVI-supported countries, 2000-2011
Basic facts about GAVIDATE
Driving equity in vaccine access
Source: WHO, Vaccine introduction database.
Hepatitis B
Routine use of vaccines in high- and low-income countries
Hib
Basic facts about GAVIDATE
Impact on the ground
Eliminating Hib meningitis in Kenya (Kilifi district)
Source: Cowgill KD et al. 2006
Basic facts about GAVIDATE
Impact on the ground
Hib meningitis in Uganda drops 85% in 4 years (3 sentinel hospitals)
Source: Lewis et al. 2008
Basic facts about GAVIDATE
Overview
1. About the GAVI Alliance
2. Accelerated vaccine uptake
3. Rising demand
4. Innovative financing
5. Shaping the market
6. Programmes of support for countries
7. Moving forward
Basic facts about GAVIDATE
Rising country demand
Countries approved and eligible for GAVI support
Source: GAVI Alliance data as at 31 July 2010
Basic facts about GAVIDATE
US$ 5.9 billion committed to countries
Source: GAVI Alliance data as at 4 November 2010
As at 4 November 2010
Basic facts about GAVIDATE
Overview
1. About the GAVI Alliance
2. Accelerated vaccine uptake
3. Rising demand
4. Innovative financing
5. Shaping the market
6. Programmes of support for countries
7. Moving forward
Basic facts about GAVIDATE
International Finance Facility for Immunisation (IFFIm)
Uses long-term donor commitments to sell AAA rated vaccine bonds
Raised US$ 3 billion since 2006
Frontloads aid through GAVI for immunisation and health systems
Has disbursed US$ 1.6 billion (June 2010) to support GAVI programmes and targeted immunisation initiatives
Basic facts about GAVIDATE
IFFIm frontloading
IFFIm donor contributions and bond issuances
Source: World Bank, December 2010
Basic facts about GAVIDATE
DonorsUp to 20-year
grants
Financial management
Country-drivenImmunisationprogrammes
InvestorsCapital market
funding
Source: World Bank
How IFFIm works
Basic facts about GAVIDATE
IFFIm donor contributions
Donors Length of commitment
Grant amount
United Kingdom 20 years£1,380 million£250 million
France 20 years €1,240 million
Italy 20 years €473.5 million
Spain 20 years €189.5 million
Sweden 15 years SEK 276.2 million
Norway 5 yearsUS$ 27 millionNOK 1,500 million
South Africa 20 years US$ 20 million
Netherlands 7 years €80 million
Approx. US$ 5.9
billion
Note: In addition, Australia has pledged to commit Australian $ 250 million to IFFIm.
Basic facts about GAVIDATE
US$ 1 billion for expanded IFFIm to support health system strengthening
“Innovation can be the key to making significant progress on reaching the MDGs, strengthening health systems and improving millions of lives – especially the lives of women and children.”
Robert Zoellick, President, World Bank
GAVI/09/Olivier Asselin
Basic facts about GAVIDATE
Accelerates the manufacture and delivery of vaccines:
Donors commit funds for new vaccines at pre-agreed price
Manufacturers get incentive to invest in R&D for new vaccines
Vaccines must meet stringent criteria and be requested by developing countries
Manufacturers legally commit to supplying vaccines at lower price long term
Long-term price paid by beneficiary countries and GAVI
Advance Market Commitment (AMC)
Basic facts about GAVIDATE
How the pneumococcal AMC pilot works:
Italy, UK, Canada, Russia, Norway, the Bill & Melinda Gates Foundation have committed to supporting pneumococcal vaccine market with US$ 1.5 billion
Manufacturers agree to supply set quantities of the vaccine for 10 years
As GAVI countries demand the vaccine, companies receive US$ 7 per dose
Companies ensure supply of remaining doses at $3.50 per dose or less
First vaccines were delivered to countries in 2010
Basic facts about GAVIDATE
AMC commitments: US$ 1.5 billion
Source: GAVI Alliance, 2009
AMC commitments US$ millions
Italy 635
United Kingdom 485
Canada 200
Russian Federation 80
Norway 50
Bill & Melinda Gates Foundation 50
Total 1,500
Basic facts about GAVIDATE
Overview
1. About the GAVI Alliance
2. Accelerated vaccine uptake
3. Rising demand
4. Innovative financing
5. Shaping the market
6. Programmes of support for countries
7. Moving forward
Basic facts about GAVIDATE
Increased competition reduces vaccine price
Number of manufacturers and price decline of pentavalent vaccine
Source: UNICEF Supply Division, 2010
Basic facts about GAVIDATE
Tiered pricing
Source: UNICEF Supply Division; CDC
Basic facts about GAVIDATE
Sustainable immunisation safety
Source: UNICEF Supply Division, 2009
Basic facts about GAVIDATE
Country co-financing: exceeding commitments
Over 40 countries co-financed vaccines in 2009 17 countries paid more than required
Basic facts about GAVIDATE
Overview
1. About the GAVI Alliance
2. Accelerated vaccine uptake
3. Rising demand
4. Innovative financing
5. Shaping the market
6. Programmes of support for countries
7. Moving forward
Basic facts about GAVIDATE
How GAVI works
Basic facts about GAVIDATE
Programmes of support for countries
New and underused vaccines
Health system strengthening
Immunisation services
Civil society organisations
Injection safety GAVI/10/Jim Holmes
Basic facts about GAVIDATE
New and underused vaccine support
New vaccines: pneumococcal and rotavirus vaccines
Underused vaccines: Hib, hepatitis B, yellow fever, measles second dose. Also:
support for the 5-in-1 pentavalent formulation
meningitis and yellow fever vaccine stockpiles
Vaccines prioritised for future support: human papillomavirus (HPV), Japanese encephalitis, rubella and typhoid vaccines
72 GAVI countries have been approved for support for at least one vaccine
Basic facts about GAVIDATE
Hepatitis B vaccine
Source: GAVI Alliance, 2010
Approved for hepatitis B vaccine support 2000 – 2010
Basic facts about GAVIDATE
Haemophilus influenzae type b vaccine
Source: GAVI Alliance, 2010
Approved for Hib vaccine support 2000 – 2010
Basic facts about GAVIDATE
Pentavalent vaccine
Source: GAVI Alliance, 2010
Approved for pentavalent vaccine support 2000 – 2010
Basic facts about GAVIDATE
Yellow fever vaccine
Source: GAVI Alliance, 2010
Approved for yellow fever vaccine support 2000 – 2010
Basic facts about GAVIDATE
Pneumococcal vaccine
Source: GAVI Alliance, 2010
Approved for pneumococcal vaccine support 2000 – 2010
Basic facts about GAVIDATE
Rotavirus vaccine
Source: GAVI Alliance, 2010
Approved for rotavirus vaccine support 2000 – 2010
Basic facts about GAVIDATE
Four new vaccines in future portfolio
Human papillomavirus (HPV): leading cause of cervical cancer, 80% of cervical cancer cases are among women in developing world
Japanese encephalitis: serious brain infection transmitted by mosquitoes, particularly in Asia
Rubella: risk of pregnant women transmitting to unborn foetus causing death or deformity
Typhoid: serious public health problem, affecting 16-22 million people per year
Basic facts about GAVIDATE
Health system strengthening (HSS) support
Strong health systems essential to expand and sustain immunisation coverage
Examples:
Health workforce
Supply, distribution, maintenance
Organisation, management
New platform for funding HSS
Partnership with the Global Fund, the World Bank and WHO
Courtesy of Aga Khan Health Services, Pakistan
Basic facts about GAVIDATE
Support to civil society organisations (CSOs)
CSOs deliver up to 60% of immunisation services in some countries
GAVI provides support:
to involve local CSOs in planning and delivery of immunisation and other child health services
to encourage cooperation and coordination between the public sector and civil society
© UNICEF/NYHQ2007-1495 Anita Khemka
Basic facts about GAVIDATE
Immunisation services support (ISS)
Flexible cash support (two-three years) to scale up immunisation services, increase coverage
Performance-based reward: US$ 20 for each additional child vaccinated with 3 doses of DTP
Helped countries reach additional 2.4 million children with DTP3
GAVI/08/Olivier Asselin
Basic facts about GAVIDATE
Injection safety support (INS)
Catalytic: three-year funding
Sustainable: countries continue to procure Autodisable (AD) syringes after GAVI support ends
Affordable: decrease in price of AD syringes
Transformative: new standards for injection safety in GAVI-supported countries
GAVI/08/Olivier Asselin
Basic facts about GAVIDATE
Women’s health and immunisation
GAVI/09/Olivier Asselin
Child and maternal mortality inextricably linked
Immunisation a platform for other child and maternal health services
GAVI supported immunisation of 40 million women against maternal and neonatal tetanus
Prioritised HPV and rubella vaccines for future portfolio
Supports strengthening of health systems to better meet needs of women and children
Basic facts about GAVIDATE
Equal immunisation coverage of girls and boys
2010 study by WHO’s Strategic Advisory Group of Experts (SAGE) on gender and immunisation found
no significant difference in immunisation coverage in girls and boys at the global level
in some countries, low status of women prevents them from accessing immunisation services for their children.
GAVI instigated the SAGE study (in collaboration with WHO and PATH) to ensure that all girls and boys have equal access
to vaccines.
Basic facts about GAVIDATE
Overview
1. About the GAVI Alliance
2. Accelerated vaccine uptake
3. Rising demand
4. Innovative financing
5. Shaping the market
6. Programmes of support for countries
7. Moving forward
Basic facts about GAVIDATE
Source/credits: WHO/UNICEF coverage estimates 1980-2009, July 2010
Over 23 million children still unimmunised
Global number of under-five children unimmunised with 3 doses of DTP
Basic facts about GAVIDATE
Causes of child deaths in low-income countries
Source: WHO, World Health Statistics 2010
Basic facts about GAVIDATE
Vaccines against major child killer diseases
Source: GAVI Alliance, 2010
Projected GAVI vaccine expenditure 2011-2015
Basic facts about GAVIDATE
Potential impact 2011 – 2015
GAVI could prevent 3.9 million future deaths in the next 4 years
Basic facts about GAVIDATE
GAVI/10/Ricci Shryock
Thank you
Basic facts about GAVIDATE
56